Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.02.22	Regeneron Pharmaceuticals Q4 Profit Increases, beats estimates (RTTNews)
04.02.22	Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results (PR Newswire)
02.02.22	Form 4 872589 (RSS)
01.02.22	Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting (PR Newswire)
31.01.22	Sanofi: CHMP Recommends Approval Of Dupixent For Children With Severe Asthma With Type2 Inflammation (RTTNews)
31.01.22	CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation (PR Newswire)
28.01.22	Regeneron, Sanofi Withdraw SBLA For Libtayo To Treat Advanced Cervical Cancer (RTTNews)
28.01.22	Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer (PR Newswire)
20.01.22	Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search (PR Newswire)
20.01.22	Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search (PR Newswire)
19.01.22	REGN : FDA Accepts For Review Libtayo-Chemotherapy Combination For Advanced Lung Cancer Treatment (RTTNews)
19.01.22	FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC (PR Newswire)
19.01.22	Sanofi Says Second Phase 3 Dupixent Trial Confirms Improvements For Patients With Prurigo Nodularis (RTTNews)
19.01.22	Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis (PR Newswire)
13.01.22	Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on (PR Newswire)
10.01.22	Form 8-K 872589 (RSS)
07.01.22	Regeneron Signs Up To $93 Mln Deal With Ultragenyx To Commercialize Evkeeza Outside U.S. (RTTNews)
07.01.22	Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States (PR Newswire)
05.01.22	Form 4 872589 (RSS)
23.12.21	Top 10 Blockbuster Drugs In 2021 (RTTNews)
23.12.21	Form 4 872589 (RSS)
22.12.21	Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
22.12.21	Alnylam Pharma Files Clinical Trial Authorization Application For ALN-APP In The UK (RTTNews)
13.12.21	Regeneron : Phase 3 Results Show Dupixen Improved Skin Clearance In Children With Atopic Dermatitis (RTTNews)
13.12.21	Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session (PR Newswire)
11.12.21	Regeneron : REGN5458 Phase 1 Data Show 75% Response Rate At Highest Dose Levels In Multiple Myeloma (RTTNews)
11.12.21	New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma (PR Newswire)
08.12.21	New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma (PR Newswire)
03.12.21	Regeneron to Participate in H.C. Wainwright & Co. Virtual Event (PR Newswire)
23.11.21	Nykode Inks Multi-mln Dollar Deal With Regeneron To Develop Cancer, Infectious Diseases Vaccines (RTTNews)
16.11.21	Regeneron Announces Investor Conference Presentations (PR Newswire)
15.11.21	Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year (PR Newswire)
13.11.21	EU Approves Regeneron Antibody Cocktail To Treat And Prevent COVID-19 (RTTNews)
12.11.21	Regeneron Announces $3 Billion Share Repurchase Program (PR Newswire)
12.11.21	Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19 (PR Newswire)
11.11.21	CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19 (PR Newswire)
08.11.21	Regeneron: REGEN-COV Show Long-term Protection Against COVID-19 In Follow-up Period (RTTNews)
08.11.21	New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19 (PR Newswire)
04.11.21	Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders (PR Newswire)
04.11.21	Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates (RTTNews)
04.11.21	Regeneron Reports Third Quarter 2021 Financial and Operating Results (PR Newswire)
25.10.21	Regeneron, Sanofi Report Positive Data From Second Phase 3 Trial Of Dupixent In EoE Patients (RTTNews)
25.10.21	Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease (PR Newswire)
22.10.21	Regeneron : Dupixent Reduces Itch And Skin Lesions In Phase 3 Trial For Prurigo Nodularis (RTTNews)
22.10.21	Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease (PR Newswire)
20.10.21	FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma (PR Newswire)
14.10.21	Regeneron Pharma: FDA To Review BLA For REGEN-COV Antibody Cocktail To Treat COVID-19 (RTTNews)
14.10.21	FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19 (PR Newswire)
11.10.21	Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021 (PR Newswire)
30.09.21	Biotech Stocks Facing FDA Decision In October 2021 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone

05.12.24

Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten